Assay ID | Title | Year | Journal | Article |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1497310 | Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 1 after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694451 | Antibacterial activity against Staphylococcus aureus NE1416 Tn mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694436 | Binding affinity to Staphylococcus aureus 70S ribosome assessed as dissociation constant by measuring reduction in BODIPY-Erythromycin A binding incubated for 1.5 hr by fluorescence polarization assay | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1497307 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus UAMS-1 after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694450 | Antibacterial activity against Staphylococcus aureus NE939 Tn mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694439 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as Vmax for DP-G1cNAc to EU- DP-G1cNAc conversion at 100 uM preincubated for 15 mins by HPLC method (Rvb = 0.235 +/- 0.049 uM/min) | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1675618 | Antibacterial activity against vancomycin-resistant Staphylococcus aureus | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
| Synthesis and biological evaluation of semi-synthetic albocycline analogs. |
AID1497315 | Inhibition of GST-tagged Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) cells preincubated with PEP and enzyme for 10 mins followed by UDP-GlcNAc addition measured after 3 hrs by HPLC analysis | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1675625 | Antibacterial activity against methicillin sensitive Staphylococcus aureus UAMS1 | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
| Synthesis and biological evaluation of semi-synthetic albocycline analogs. |
AID1694456 | Synergistic antibacterial activity against Staphylococcus aureus UAMS-1 AlbR D resistant mutant assessed as fractional inhibitory concentration index in presence of fosfomycin by broth microdilution assay | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694440 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as Vmax for DP-G1cNAc to EU- DP-G1cNAc conversion at 150 uM preincubated for 15 mins by HPLC method (Rvb = 0.235 +/- 0.049 uM/min) | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1497312 | Cytotoxicity against human HepG2 cells at <= 64 ug/ml by MTT assay | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1497311 | Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 10 after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1497317 | Inhibition of GST-tagged Escherichia coli MurA expressed in Escherichia coli BL21(DE3) cells preincubated with PEP and enzyme for 10 mins followed by UDP-GlcNAc addition measured after 3 hrs by HPLC analysis | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1497309 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694455 | Synergistic antibacterial activity against Staphylococcus aureus UAMS-1 AlbR C resistant mutant assessed as fractional inhibitory concentration index in presence of fosfomycin by broth microdilution assay | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694442 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as Kcat for DP-G1cNAc to EU- DP-G1cNAc conversion at 100 uM preincubated for 15 mins by HPLC method (Rvb = 0.471 +/- 0.994 /min) | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1497305 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1497316 | Inhibition of GST-tagged Staphylococcus aureus MurZ expressed in Escherichia coli BL21(DE3) cells preincubated with PEP and enzyme for 10 mins followed by UDP-GlcNAc addition measured after 3 hrs by HPLC analysis | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694453 | Synergistic antibacterial activity against Staphylococcus aureus UAMS-1 AlbR A resistant mutant assessed as fractional inhibitory concentration index in presence of fosfomycin by broth microdilution assay | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1497313 | Inhibition of GST-tagged Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) cells assessed as reduction in EP-UDP-GlcNAc production at 650 uM preincubated with UDP-GlcNAc and enzyme for 10 mins followed by PEP addition measured after 3 hrs | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694448 | Antibacterial activity against Staphylococcus aureus UAMS-1 AlbR D resistant mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1675624 | Antibacterial activity against methicillin resistant Staphylococcus aureus USA300 | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
| Synthesis and biological evaluation of semi-synthetic albocycline analogs. |
AID1497314 | Inhibition of GST-tagged Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) cells assessed as reduction in EP-UDP-GlcNAc production at 650 uM preincubated with PEP and enzyme for 10 mins followed by UDP-GlcNAc addition measured after 3 hrs | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694449 | Antibacterial activity against Staphylococcus aureus USA300 Tn mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694438 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as Vmax for DP-G1cNAc to EU- DP-G1cNAc conversion at 50 uM preincubated for 15 mins by HPLC method (Rvb = 0.235 +/- 0.049 uM/min) | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694441 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as Kcat for DP-G1cNAc to EU- DP-G1cNAc conversion at 50 uM preincubated for 15 mins by HPLC method (Rvb = 0.471 +/- 0.994 /min) | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1675619 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
| Synthesis and biological evaluation of semi-synthetic albocycline analogs. |
AID1497306 | Antibacterial activity against Escherichia coli RFM795 harboring lptD gene mutant after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1497318 | Antibacterial activity against methicillin-resistant Staphylococcus aureus | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694446 | Antibacterial activity against Staphylococcus aureus UAMS-1 AlbR B resistant mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694457 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as using DP-G1cNAc as substrate preincubated for 15 mins by HPLC method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694452 | Synergistic antibacterial activity against Staphylococcus aureus UAMS-1 assessed as fractional inhibitory concentration index in presence of fosfomycin by broth microdilution assay | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1497308 | Antibacterial activity against methicillin-resistant Staphylococcus aureus LAC JE2 after 16 hrs by broth micro dilution method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1497319 | Inhibition of Staphylococcus aureus MurA assessed as reduction in [3H]GlcNAc uptake | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. |
AID1694445 | Antibacterial activity against Staphylococcus aureus UAMS-1 AlbR A resistant mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1675620 | Antibacterial activity against methicillin resistant Staphylococcus aureus | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
| Synthesis and biological evaluation of semi-synthetic albocycline analogs. |
AID1694443 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli BL21(DE3) assessed as Kcat for DP-G1cNAc to EU- DP-G1cNAc conversion at 150 uM preincubated for 15 mins by HPLC method (Rvb = 0.471 +/- 0.994 /min) | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694444 | Antibacterial activity against Staphylococcus aureus UAMS-1 assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694454 | Synergistic antibacterial activity against Staphylococcus aureus UAMS-1 AlbR B resistant mutant assessed as fractional inhibitory concentration index in presence of fosfomycin by broth microdilution assay | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
AID1694447 | Antibacterial activity against Staphylococcus aureus UAMS-1 AlbR C resistant mutant assessed as growth inhibition incubated at 16 to 24 hrs by CLSI method | 2021 | Bioorganic & medicinal chemistry, 02-15, Volume: 32 | Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |